Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis

References

• Tefferi A. Myelofibrosis with myeloid metaplasia. N Eng J Med 2000;342(17):1255–1265
   PubMed Web of Science ®Google Scholar
• Villeval JL, James C, Pisani DF, Casadevall N, Vainchenker W. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. Semin Thrombosis Hemostasis 2006;32(4 Pt 2):341–351
   PubMed Web of Science ®Google Scholar
• Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984;64(1):1–12
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larran A, Arellano-Rodrigo E, Granell M, Domingo A, Montserrat E. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: Analysis in a series of 155 patients from a single institution. Leukemia 2006;20(1):55–60
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G, Barosi G. Thrombosis in primary myelofibrosis: Incidence and risk factors. Blood 2010;115(4):778–782
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi MC, Finazzi G. Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 2012;26(5):205–211
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology 2012;2012:571–581
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Pieri L, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012;119(10):2239–2241
   PubMed Web of Science ®Google Scholar
• Danielsson S, Merup M, Olsson L, Palmblad J, Astrom M. [X-linked thrombocytopenia with thalassemia in two families in Sweden. Consider hereditary causes of thrombocytopenia and bone marrow fibrosis]. Lakartidningen 2012;109(34–35):1474–1477
   PubMedGoogle Scholar
• Ciovacco WA, Raskind WH, Kacena MA. Human phenotypes associated with GATA-1 mutations. Gene 2008;427(1–2):1–6
   PubMed Web of Science ®Google Scholar
• Balduini CL, Pecci A, Loffredo G, Izzo P, Noris P, Grosso M, Bergamaschi G, Rosti V, Magrini U, Ceresa IF, et al. Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. Thrombosis Haemostasis 2004;91(1):129–140
   PubMed Web of Science ®Google Scholar
• Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thrombosis Res 2002;108(2–3):139–145
   PubMed Web of Science ®Google Scholar
• McDevitt MA, Shivdasani RA, Fujiwara Y, Yang H, Orkin SH. A “knockdown” mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci USA 1997;94(13):6781–6785
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Bianchi L, Cellai C, Paoletti F, Rana RA, Lorenzini R, Migliaccio G, Migliaccio AR. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood 2002;100(4):1123–1132
   PubMed Web of Science ®Google Scholar
• Zingariello M, Fabucci ME, Bosco D, Migliaccio AR, Martelli F, Rana RA, Lorenzini R, Migliaccio G, Migliaccio AR. Differential localization of P-selectin and von Willebrand factor during megakaryocyte maturation. Biotechnic Histochem 2010;85(3):157–170
   PubMed Web of Science ®Google Scholar
• McDevitt MA, Fujiwara Y, Shivdasani RA, Orkin SH. An upstream, DNase I hypersensitive region of the hematopoietic-expressed transcription factor GATA-1 gene confers developmental specificity in transgenic mice. Proc Natl Acad Sci USA 1997;94:7976–7981
   PubMed Web of Science ®Google Scholar
• Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 1999;93:2867–2875
   PubMed Web of Science ®Google Scholar
• Migliaccio AR, Rana RA, Sanchez M, Lorenzini R, Centurione L, Bianchi L, et al. GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant. J Exp Med 2003;197(3):281–296
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Bianchi L, Cellai C, Paoletti F, Carrai V, Calzolari A, Vannucchi AM, Migliaccio G, Orkin SH. Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression (GATA-1(low) mice). Blood 2001;97(10):3040–3050
   PubMed Web of Science ®Google Scholar
• Robinson SD, Frenette PS, Rayburn H, Cummiskey M, Ullman-Cullere M, Wagner DD, Hynes RO. Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leukocyte recruitment. Proc Natl Acad Sci USA 1999;96(20):11452–11457
   PubMed Web of Science ®Google Scholar
• Hartwell DW, Butterfield CE, Frenette PS, Kenyon BM, Hynes RO, Folkman J, Wagner DD. Angiogenesis in P- and E-selectin-deficient mice. Microcirculation 1998;5(2–3):173–178
   PubMed Web of Science ®Google Scholar
• Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood 2000;95(4):1317–1323
   PubMed Web of Science ®Google Scholar
• Murad JP, Espinosa EV, Ting HJ, Khasawneh FT. Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan. J Cardiovasc Pharmacol Therap 2012;17(3):308–314
   PubMed Web of Science ®Google Scholar
• Migliaccio AR, Martelli F, Verrucci M, Sanchez M, Valeri M, Migliaccio G, Vannucchi AM, Zingariello M, Di Baldassarre A, Ghinassi B, et al. Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation. Blood 2009;114(10):2107–2120
   PubMed Web of Science ®Google Scholar
• Migliaccio AR, Martelli F, Verrucci M, Migliaccio G, Vannucchi AM, Ni H, Xu M, Jiang Y, Nakamoto B, Papayannopoulou T, et al. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol 2008;36(2):158–171
   PubMed Web of Science ®Google Scholar
• Ghinassi B, Sanchez M, Martelli F, Amabile G, Vannucchi AM, Migliaccio G, Xu M, Jiang Y, Nakamoto B, Papayannopoulou T, et al. The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor. Blood 2007;109(4):1460–1471
   PubMed Web of Science ®Google Scholar
• Falcieri E, Bassini A, Pierpaoli S, Luchetti F, Zamai L, Vitale M, Guidotti L, Zauli G. Ultrastructural characterization of maturation, platelet release, and senescence of human cultured megakaryocytes. Anat Rec 2000;258(1):90–99
   PubMedGoogle Scholar
• Yanada M, Kojima T, Ishiguro K, Nakayama Y, Yamamoto K, Matsushita T, Kadomatsu K, Nishimura M, Muramatsu T, Saito H. Impact of antithrombin deficiency in thrombogenesis: Lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood 2002;99(7):2455–2458
   PubMed Web of Science ®Google Scholar
• Cerletti C, de Gaetano G, Lorenzet R. Platelet – leukocyte interactions: Multiple links between inflammation, blood coagulation and vascular risk. Mediterranean J Hematol Infect Dis 2010;2(3):e2010023
   PubMedGoogle Scholar
• Huo Y, Xia L. P-selectin glycoprotein ligand-1 plays a crucial role in the selective recruitment of leukocytes into the atherosclerotic arterial wall. Trends Cardiovasc Med 2009;19(4):140–145
   PubMed Web of Science ®Google Scholar
• del Conde I, Nabi F, Tonda R, Thiagarajan P, Lopez JA, Kleiman NS. Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. Arteriosclerosis, thrombosis, and vascular biology. 2005;25(5):1065–1070
   Google Scholar
• Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G. Platelet-leukocyte interactions in thrombosis. Thrombosis Res 2012;129(3):263–266
   PubMed Web of Science ®Google Scholar
• Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arteriosclerosis Thrombosis Vascular Biol 2010;30(12):2357–2361
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001;103(4):491–495
   PubMed Web of Science ®Google Scholar
• Linden MD, Furman MI, Frelinger AL, 3rd, Fox ML, Barnard MR, Li Y, Przyklenk K, Michelson AD. Indices of platelet activation and the stability of coronary artery disease. J Thrombosis Haemostasis 2007;5(4):761–765
   PubMed Web of Science ®Google Scholar
• Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA 2000;97(25):13835–13840
   PubMed Web of Science ®Google Scholar
• Ramacciotti E, Hawley AE, Farris DM, Ballard NE, Wrobleski SK, Myers DD Jr., Henke PK, Wakefield TW. Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. Thrombosis Haemostasis 2009;101(4):748–754
   PubMed Web of Science ®Google Scholar
• Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197(11):1585–1598
   PubMed Web of Science ®Google Scholar
• Dean WL, Lee MJ, Cummins TD, Schultz DJ, Powell DW. Proteomic and functional characterisation of platelet microparticle size classes. Thrombosis Haemostasis 2009;102(4):711–718
   PubMed Web of Science ®Google Scholar
• Dashevsky O, Varon D, Brill A. Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer 2009;124(8):1773–1777
   PubMed Web of Science ®Google Scholar
• Owens AP, 3rd Mackman N. Microparticles in hemostasis and thrombosis. Circulation Res 2011;108(10):1284–1297
   PubMed Web of Science ®Google Scholar
• Karakantza M, Giannakoulas NC, Zikos P, Sakellaropoulos G, Kouraklis A, Aktypi A, Metallinos IC, Theodori E, Zoumbos NC, Maniatis A. Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera. Int J Hematol 2004;79(3):253–259
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33(5):523–530
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thrombosis Hemostasis 2007;33(4):313–320
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109(6):2310–2313
   PubMed Web of Science ®Google Scholar
• Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008;26(16):2732–2736
   PubMed Web of Science ®Google Scholar
• Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012;26(4):716–719
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC, Domingo A, Villamor N, Colomer D, Cervantes F. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol 2008;87(4):269–276
   PubMed Web of Science ®Google Scholar